tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2012 Jan 1;8(1). [Epub ahead of print]
Economic value of influenza vaccination.
de Waure C, Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, Ricciardi W.
Source
Institute of Hygiene, Catholic University of the Sacred Heart; Rome, Italy.
Abstract
Influenza epidemics are responsible for high mortality and morbidity rates in particular among elderly and high risk groups. This review is aimed at assessing the economic value of vaccination in these groups. A search of full economic evaluations of influenza vaccination in comparison with no interventions was performed on PubMed from January 1990 to May 2011. Only economic evaluations dealing with elderly and high risk groups were considered. The quality of selected articles was assessed through Drummond's checklist. Sixteen cost-effectiveness analyses and four cost-benefit analyses were included: overall, the quality of studies was fairly good. The vaccination was demonstrated to be cost-effective or cost-saving in almost all studies, independently by the perspective and the type of analysis. Influenza vaccination is a worthwhile intervention from the pharmacoeconomic view-point, anyway a standardization of methods should be desirable in order to guarantee the comparability and transferability of results.
PMID:
22251999
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22251999
Economic value of influenza vaccination.
de Waure C, Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, Ricciardi W.
Source
Institute of Hygiene, Catholic University of the Sacred Heart; Rome, Italy.
Abstract
Influenza epidemics are responsible for high mortality and morbidity rates in particular among elderly and high risk groups. This review is aimed at assessing the economic value of vaccination in these groups. A search of full economic evaluations of influenza vaccination in comparison with no interventions was performed on PubMed from January 1990 to May 2011. Only economic evaluations dealing with elderly and high risk groups were considered. The quality of selected articles was assessed through Drummond's checklist. Sixteen cost-effectiveness analyses and four cost-benefit analyses were included: overall, the quality of studies was fairly good. The vaccination was demonstrated to be cost-effective or cost-saving in almost all studies, independently by the perspective and the type of analysis. Influenza vaccination is a worthwhile intervention from the pharmacoeconomic view-point, anyway a standardization of methods should be desirable in order to guarantee the comparability and transferability of results.
PMID:
22251999
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22251999